Digestive Diseases and Sciences

, Volume 52, Issue 6, pp 1540–1547 | Cite as

Antiviral Response of HCV Genotype 1 to Consensus Interferon and Ribavirin Versus Pegylated Interferon and Ribavirin

  • Maria H. Sjogren
  • Robert SjogrenJr.
  • Michael F. Lyons
  • Michael Ryan
  • John Santoro
  • Coleman Smith
  • K. Rajender Reddy
  • Herbert Bonkovsky
  • Brooke Huntley
  • Sima Faris-Young
Original Article


Achieving an antiviral response at a reasonable cost is a challenge in the treatment of patients with chronic hepatitis C. A previous study indicated that consensus interferon with ribavirin had promising activity against hepatitis C virus (HCV) genotype 1. The objective of this study was to determine the virologic response with consensus interferon or pegylated interferon α-2b plus weight-ribavirin in patients chronically infected with HCV genotype 1. Intention-to-treat analysis showed response in 37% and 41% of subjects treated with consensus interferon/ribavirin or pegylated interferon/ribavirin, respectively, with response rates of 42% and 44% observed in analysis of the per-protocol population, not a significant difference. Tolerability of the two treatment regimens was similar. In conclusion, both treatment regimens were safe and gave a similar antiviral response. It is possible that if consensus interferon is administered daily rather than three times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1.


Viral hepatitis Viral load Depression Quality of life African-American Interferon alfacon-1 



This work was supported in part by a grant from InterMune.


  1. 1.
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341(8):556–562PubMedCrossRefGoogle Scholar
  2. 2.
    Gish RG, Afdhal NH, Dieterich DT, Reddy KR (2005) Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 3(4):311–318PubMedCrossRefGoogle Scholar
  3. 3.
    Hoofnagle JH (2002) Course and outcome of hepatitis C. Hepatology 36(5; Suppl 1):S21–S29PubMedCrossRefGoogle Scholar
  4. 4.
    Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39(4):1147–1171PubMedCrossRefGoogle Scholar
  5. 5.
    Fried MW, Shiffman ML, Reddy KR, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975–982PubMedCrossRefGoogle Scholar
  6. 6.
    Manns MP, McHutchison JG, Gordon SC, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958–965PubMedCrossRefGoogle Scholar
  7. 7.
    Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39(6):1702–1708PubMedCrossRefGoogle Scholar
  8. 8.
    Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350(22):2265–2271PubMedCrossRefGoogle Scholar
  9. 9.
    Sjogren MH, Sjogren R, Holtzmuller K, et al. (2005) Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 50(4):727–732PubMedCrossRefGoogle Scholar
  10. 10.
    Blatt LM, Mutchnick MG, Tong MJ, et al. (2000) Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 7(3):196–202PubMedCrossRefGoogle Scholar
  11. 11.
    Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH (1996) Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125(8):634–639PubMedGoogle Scholar
  12. 12.
    Blatt LM, Davis JM, Klein SB, Taylor MW (1996) The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 16(7):489–499PubMedCrossRefGoogle Scholar
  13. 13.
    Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW (1992) A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 12(1):55–59PubMedGoogle Scholar
  14. 14.
    Tong MJ, Reddy KR, Lee WM, et al. (1997) Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 26(3):747–754PubMedCrossRefGoogle Scholar
  15. 15.
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMedGoogle Scholar
  16. 16.
    Clark CH, Mahoney JS, Clark DJ, Eriksen LR (2002) Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D). J Adv Nurs 40(3):361–369PubMedCrossRefGoogle Scholar
  17. 17.
    Kleinman L, Zodet MW, Hakim Z, et al. (2000) Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 9(5):499–508PubMedCrossRefGoogle Scholar
  18. 18.
    Ware JE, Jr., Bayliss MS, Mannocchia M, Davis GL (1999) Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 30(2):550–555PubMedCrossRefGoogle Scholar
  19. 19.
    Leevy CB, Chalmers CP, Blatt LM (2005) Predictive model and sustained virologic response for PEG IFN-alfa-2+ weight-based ribavirin nonresponders re-treated with IFN alfacon-1 + weight-based ribavirin. Gastroenterology 128:S1538CrossRefGoogle Scholar
  20. 20.
    Ferenci P (2004) Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 24(Suppl 2):25–31PubMedCrossRefGoogle Scholar
  21. 21.
    Perelson AS, Herrmann E, Micol F, Zeuzem S (2005) New kinetic models for the hepatitis C virus. Hepatology 42(4):749–754PubMedCrossRefGoogle Scholar
  22. 22.
    Fish EN, Banerjee K, Stebbing N (1989) The role of three domains in the biological activity of human interferon-alpha. J Interferon Res 9(1):97–114PubMedGoogle Scholar
  23. 23.
    Klein SB, Blatt LM, Taylor MW (1993) Consensus interferon induces peak mRNA accumulation at lower concentrations than interferon-alpha 2a. J Interferon Res 13(5):341–347PubMedGoogle Scholar
  24. 24.
    Blatt LM, Radhakrishnan R, Seiwert S, Tan H, Cheung E (2005) Biological characterization of PEG alfacon-1 in vitro: comparison of biological potency to the parent molecule interferon alfacon-1. Gastroenterology 128:S915Google Scholar
  25. 25.
    Schaefer M, Schwaiger M, Garkisch AS, et al. (2005) Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 42(6):793–798PubMedCrossRefGoogle Scholar
  26. 26.
    Fried MW (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36(5; Suppl 1):S237–S244PubMedCrossRefGoogle Scholar
  27. 27.
    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–1123PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Maria H. Sjogren
    • 1
  • Robert SjogrenJr.
    • 2
  • Michael F. Lyons
    • 3
  • Michael Ryan
    • 4
  • John Santoro
    • 5
  • Coleman Smith
    • 6
  • K. Rajender Reddy
    • 7
  • Herbert Bonkovsky
    • 8
  • Brooke Huntley
    • 1
  • Sima Faris-Young
    • 9
  1. 1.Walter Reed Army Medical CenterWashingtonUSA
  2. 2.Kaiser PermanenteFalls ChurchUSA
  3. 3.Tacoma Digestive Diseases CenterTacomaUSA
  4. 4.Digestive and Liver Disease SpecialistsNorfolkUSA
  5. 5.Atlantic Gastroenterology Associates Egg Harbor Township New JerseyEgg Harbor TownshipUSA
  6. 6.Minnesota GastroenterologySt. PaulUSA
  7. 7.UPenn GI ResearchPhiladelphiaUSA
  8. 8.UConn Health CenterFarmingtonUSA
  9. 9.Intermune, Inc.BrisbaneUSA

Personalised recommendations